Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study
| Autor: | Ying Gao, Shuo Xiao, Kaeli B Miller, Yuchen Li, Yanjie Zhao, Feng Shi, Chen-Xu Qu, Qingkun Song, Hong Chang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology PD-L1 medicine.medical_specialty Esophageal squamous cell carcinoma OncoTargets and Therapy 03 medical and health sciences 0302 clinical medicine Immune system Internal medicine medicine Overall survival tumor microenvironment Pharmacology (medical) tumor cells and immune cells Original Research Tumor microenvironment biology business.industry Retrospective cohort study esophageal squamous cell carcinoma 030104 developmental biology Interactive effects 030220 oncology & carcinogenesis biology.protein Pd l1 expression prognosis business |
| Zdroj: | OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | Feng Shi,1 Shuo Xiao,2 Kaeli B Miller,2 Yanjie Zhao,3 Yuchen Li,4 Ying Gao,1 Hong Chang,1 Qingkun Song,5,6 Chenxu Qu7 1Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, People’s Republic of China; 2Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA; 3Department of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, People’s Republic of China; 4Sid Faithfull Brain Cancer Research Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; 5Department of Clinical Epidemiology and Evidence-based Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, People’s Republic of China; 6Beijing Key Laboratory of Cancer Therapeutic Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, People’s Republic of China; 7Gruber Laboratory, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USACorrespondence: Qingkun SongDepartment of Clinical Epidemiology and Evidence-based Medicine, Beijing Shijitan Hospital, Capital Medical University, Tieyi Road 10, Haidian District, Beijing 100038, People’s Republic of ChinaTel +86-10-63926901Email songqingkun@ccmu.edu.cnPurpose: The present study aimed to investigate the prognostic effect of PD-L1 expressing in tumor and immune cells among patients with esophageal squamous cell carcinoma.Patients and Methods: We performed a retrospective cohort study by consecutively recruiting 142 patients. The clinicopathological features and PD-L1 expression on tumor and immune cells were independently evaluated by two pathologists.Results: The median expression rate of PD-L1 was 5% and 30% in tumor and immune cells, respectively. Patients with higher expression of PD-L1 in tumor cells had shorter disease-free and overall survival, and the HRs were 1.52 for relapse (95% CI: 0.88, 2.60) and 1.48 for death (95% CI: 0.82, 2.69). There was no significant association between the PD-L1 expression in immune cells and survival. However, among the patients with PD-L1 expression rate ≤ 30% in immune cells, the high expression rate of PD-L1 in tumor cells was significantly associated with the relapse and death, with HRs of 2.51 (95% CI: 1.25, 5.06) and 3.51 (95% CI: 1.57, 7.85), respectively. Among patients with PD-L1 expression rate > 30% in immune cells, the PD-L1 expression in tumor cells did not show any association with the disease-free and overall survival.Conclusion: Our study demonstrates that the integration of PD-L1 expression in tumor and immune cells could be used to predict the relapse and survival among patients with esophageal squamous cell carcinoma.Keywords: esophageal squamous cell carcinoma, PD-L1, prognosis, tumor cells and immune cells, tumor microenvironment |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|